What is CUSIP 29014R103?

CUSIP 29014R103 is the security identifier used in SEC filing datasets for ELOX - Eloxx Pharmaceuticals Inc - Common Stock, $0.01 par value per share.

Security Snapshot

Eloxx Pharmaceuticals Inc - Common Stock, $0.01 par value per share (ELOX) Institutional Ownership

Q: Who owns ELOX - Eloxx Pharmaceuticals Inc - Common Stock, $0.01 par value per share based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

CUSIP: 29014R103

13F Institutional Holders and Ownership History from Q2 2018 to Q1 2023

13F reference period

n/a

Institutions Reporting

Shares (Excl. Options)

n/a

Price

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Security type / class: Equity / Common Stock, $0.01 par value per share
Symbol: ELOX on OTC
Shares outstanding: 4,036,327

13F Shares, Excluding Options vs Price

13F Value, Excluding Options

Total Investors

Filing notes and source

Key facts

ELOX - Eloxx Pharmaceuticals Inc - Common Stock, $0.01 par value per share is tracked under CUSIP 29014R103.
13F reference-period holder data is not available.
3 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder data for the Q2 2026 reference period is not available.
Available periods remain in the history table; they do not substitute for the headline period.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

29014R103

13F reference period

n/a

13F holders

13D/G owners

CIK / CUSIP context first

ELOX full holder history Eloxx Pharmaceuticals, Inc. SEC filings Eloxx Pharmaceuticals, Inc. company facts Eloxx Pharmaceuticals, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 29014R103:

Q1 2023 (0 holders) Q4 2022 (1 holder) Q3 2022 (25 holders) Q2 2022 (27 holders) Q1 2022 (33 holders) Q4 2021 (37 holders) Q3 2021 (38 holders) Q2 2021 (46 holders) Q1 2021 (38 holders) Q4 2020 (41 holders)

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows

Security

ELOX

Filer	Ownership	Change %	Nb Shares	Change %	Reporting Name	Report Period
Domicilium Real Estate Fund III LP	19%		1,407,138		Domicilium Capital Partners LLC	27 Apr 2026
Coastlands Capital LP	10%	+100%	410,530	+54%	Coastlands Capital LP	10 Jun 2026
Aberdeen Group plc	9.9%		400,000		Aberdeen Group plc	30 Jun 2026

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods

Headline period

n/a

Rows shown

1-20 of 20

Period	13F Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2023 Q1	0	$0	-$27,000				0
2022 Q4	14,626	$27,000	-$3,088,926			$1.85	1
2022 Q3	12,663,089	$2,135,083	-$59,330		$0	$0.17	25
2022 Q2	13,000,142	$3,506,132	-$855,125		$3,000	$0.27	27
2022 Q1	15,039,933	$8,417,274	-$928,950	$0	$0	$0.56	33
2021 Q4	16,516,778	$11,652,457	-$991,710	$24,000	$15,000	$0.71	37
2021 Q3	16,102,160	$26,032,201	-$1,450,114	$307,000	$301,000	$1.63	38
2021 Q2	16,668,137	$33,173,467	+$15,534,148	$411,000	$282,000	$1.99	46
2021 Q1	8,641,624	$28,688,126	-$207,922	$0		$3.32	38
2020 Q4	8,695,626	$34,454,454	+$292,285	$232,000		$3.98	41
2020 Q3	8,626,106	$22,684,084	-$240,155			$2.63	38
2020 Q2	8,703,145	$26,363,805	+$294,850			$3.03	40
2020 Q1	8,694,893	$17,041,323	-$3,545,205			$1.96	40
2019 Q4	8,633,469	$63,520,712	-$552,703			$7.36	46
2019 Q3	9,394,620	$42,434,435	-$3,360,998			$4.52	49
2019 Q2	9,708,346	$96,776,248	+$22,379,301			$9.97	48
2019 Q1	7,549,121	$88,167,850	+$687,467			$11.68	41
2018 Q4	7,484,952	$89,888,326	+$7,850,421			$12.01	39
2018 Q3	6,828,729	$116,331,249	+$23,962,345			$17.04	38
2018 Q2	5,421,392	$91,247,341	+$91,235,340			$17.07	41